Bryn Mawr Capital Management LLC Acquires 1,081 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Bryn Mawr Capital Management LLC raised its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 109.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,070 shares of the medical research company's stock after purchasing an additional 1,081 shares during the period. Bryn Mawr Capital Management LLC's holdings in Laboratory Co. of America were worth $475,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of LH. Capital City Trust Co. FL raised its stake in Laboratory Co. of America by 1.5% during the 4th quarter. Capital City Trust Co. FL now owns 15,553 shares of the medical research company's stock valued at $3,567,000 after acquiring an additional 223 shares in the last quarter. OneDigital Investment Advisors LLC raised its stake in shares of Laboratory Co. of America by 115.7% during the third quarter. OneDigital Investment Advisors LLC now owns 6,088 shares of the medical research company's stock valued at $1,361,000 after purchasing an additional 3,265 shares in the last quarter. Alexander Randolph Advisory Inc. acquired a new stake in Laboratory Co. of America in the third quarter worth about $955,000. Wealthcare Advisory Partners LLC grew its position in Laboratory Co. of America by 23.9% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company's stock valued at $583,000 after buying an additional 490 shares in the last quarter. Finally, Mutual of America Capital Management LLC bought a new stake in shares of Laboratory Co. of America during the 3rd quarter worth about $2,316,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Laboratory Co. of America Trading Up 1.2 %

LH traded up $2.97 during mid-day trading on Monday, reaching $254.01. The stock had a trading volume of 721,779 shares, compared to its average volume of 583,403. The firm's fifty day simple moving average is $241.20 and its two-hundred day simple moving average is $232.78. The stock has a market capitalization of $21.25 billion, a P/E ratio of 28.80, a P/E/G ratio of 1.71 and a beta of 1.07. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $258.59. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. On average, equities analysts predict that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be given a $0.72 dividend. The ex-dividend date is Thursday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.13%. Laboratory Co. of America's dividend payout ratio is currently 32.65%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on LH shares. Barclays cut their target price on Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating for the company in a research report on Friday, February 7th. Morgan Stanley raised their target price on Laboratory Co. of America from $260.00 to $270.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. UBS Group dropped their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Evercore ISI raised shares of Laboratory Co. of America from an "in-line" rating to an "outperform" rating and upped their price target for the company from $260.00 to $265.00 in a report on Tuesday, January 7th. Finally, Piper Sandler lifted their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $265.75.

Insider Buying and Selling

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 1,314 shares of Laboratory Co. of America stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $251.30, for a total transaction of $330,208.20. Following the transaction, the executive vice president now directly owns 2,171 shares in the company, valued at approximately $545,572.30. The trade was a 37.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Amy B. Summy sold 226 shares of Laboratory Co. of America stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $250.40, for a total value of $56,590.40. Following the transaction, the chief marketing officer now owns 4,544 shares in the company, valued at $1,137,817.60. This trade represents a 4.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,661 shares of company stock valued at $2,119,118 over the last three months. Company insiders own 0.85% of the company's stock.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.